Prospective Grant of Exclusive License: Novel Method of O- Demethylation and N-Deprotection of Opioid Compounds

Riepilogo

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license in the United States to practice the invention embodied in: U.S. Patent Application Serial No. 60/018,027, filed May 21, 1996, entitled, ``Novel Method of O-Demethylation of Opium Alkaloids and Derivatives''; and U.S. Patent Application Serial No. 60/ 020,215, filed June 21, 1996, entitled, ``Novel Method of O- Demethylation and N-Deprotection of Opioid Compounds''; to Mallinckrodt Chemical, Inc., having a place of business in Chesterfield, Missouri. The patent rights in these inventions have been assigned to the United States of America. The patents and patent applications claim improvements to the synthesis method for synthetic medicinal opiates that produce high yields. O-demethylation and N-deprotection are key steps in the synthesis of opioid compounds. The methods of these inventions accomplish these procedures without the use of toxic or carcinogenic reagents. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditi